Eurofins Amatsigroup

Active

Public limited companyfounded 200718 yrs activeIndustriepark-Zwijnaarde 7B, 9052 Gent, BelgiumKBO/BCE: BE 0893.062.073

Summary

Eurofins Amatsigroup has been active since 2007 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €4.58M and a net result of €1.80M. Equity remains stable across the filed fiscal years (±0.4% per year). Its solvency ranks better than 41% of 1247 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.1% (very low).

Watch Print / PDF

Checked score

Score 2024

85 / 100

Excellent

The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.

Axes · tick = 2023

Profitability88▲+17

Solvency70▼-4

Growth77▼-1

Track record100

Bankruptcy probability, 12 months

0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Credit up to €380k at 30 days acceptable

Liquidity ample (current ratio 1.5 against 1.51 in 2023; short-term debt: 45% and cash: 39.3% of total assets), but 55.2% of the assets are financed with debt.

How do we compute the score and the probability?

Credit check for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Lower-failure-rate sector

In this sector companies fail less often than the Belgian average.

Gazette · bankruptcies per sector, NACE 86

Relative position

BE, all sectors

reference

Sector 86

lower

← fewer bankruptcies more bankruptcies →

Multiple establishment units

Several establishment units mean more fixed costs, and such companies fail more often than a company with one establishment.

KBO · establishment units

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2024

Solvency, return and age of the figures

Solvency

44.8%

Return on assets

17.6%

Age of the figures

21 mo

Latest accounts filed on time

The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 01-07-2025, 30 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

not confirmed

2024

30 d early

2023

56 d early

2022

45 d early

2021

30 d early

2020

45 d early

2019

60 d late

← before the deadline after the deadline →

Checked, nothing found (1)

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2024, full schema

Turnover

€23.60M▲ 8.1%

2023 · €21.84M

2018: €11.70M 2019: €16.56M 2020: €19.33M 2021: €19.89M 2022: €21.47M 2023: €21.84M

2018 → 2024

EBIT margin

9.5%▲ 5.4pp

2023 · 4.1%

2018: -12.3% 2019: 5.0% 2020: 6.2% 2021: 12.6% 2022: 8.1% 2023: 4.1%

2018 → 2024

Net result

€1.80M▲ 224%

2023 · €557k

2018: €-1.45M 2019: €603k 2020: €957k 2021: €1.76M 2022: €1.20M 2023: €557k

2018 → 2024

Working capital

€2.32M▲ 21.3%

2023 · €1.91M

2018: €2.36M 2019: €1.56M 2020: €2.35M 2021: €886k 2022: €861k 2023: €1.91M

2018 → 2024

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20202021202220232024Trend

Turnover€19.33M-€19.89M▲ 2.9%€21.47M▲ 7.9%€21.84M▲ 1.7%€23.60M▲ 8.1%

Equity€4.58M-€4.58M=€4.58M=€4.58M=€4.58M=

Operating result€1.19M-€2.50M▲ 110%€1.73M▼ 30.7%€898k▼ 48.1%€2.24M▲ 149%

Net result€957k-€1.76M▲ 84.2%€1.20M▼ 32.1%€557k▼ 53.5%€1.80M▲ 224%

Result per fiscal year

Operating resultNet result

The operating result recovers in 2024; 2024 is 149% above 2023.

Balance-sheet composition

2024 in colour, 2023 as the grey bar beneath

Assets €10.22M

32.3%

67.7%

Fixed assets €3.30M ▼ 10.6%

Current assets €6.92M ▲ 22.8%

Equity and liabilities €10.22M

44.8%

55.2%

Equity €4.58M =

Debt €5.64M ▲ 18.9%

Debt's share of the balance-sheet total rises from 50.9% to 55.2%. Debt is higher.

Key figures and ratios

2024 value · change against 2023

EBITDA

€3.60M▲

2023 · €2.26M

Cash flow

€3.17M▲

2023 · €1.92M

Current ratio

1.50▼

2023 · 1.51

Quick ratio

1.36▼

2023 · 1.40

Debt to equity

1.23▲

2023 · 1.04

ROE

39.4%▲

2023 · 12.2%

ROA

17.6%▲

2023 · 6.0%

Interest coverage

58.79▼

2023 · 60.07

Debt ≤ 1 year

€4.60M▲

2023 · €3.72M

Debt > 1 year

€1.00M=

2023 · €1.00M

Income taxes

€690k▲

2023 · €284k

Staff costs

€7.82M▼

2023 · €8.37M

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Filed annual accounts As filed with the NBB · 2024 against 2023 · 78 lines

Balance sheet Code20232024

Assets

Total assets20/58€9.32M€10.22M▲

Fixed assets21/28€3.69M€3.30M▼

Intangible fixed assets21€5k€25k▲

Tangible fixed assets22/27€3.68M€3.27M▼

Land and buildings22€176k€99k▼

Plant, machinery and equipment23€2.29M€2.37M▲

Furniture and vehicles24€1.10M€788k▼

Leasing and similar rights25€6k€0▼

Assets under construction and advance payments27€113k€14k▼

Financial fixed assets28€7k€5k▼

Other financial fixed assets284/8€7k€5k▼

Amounts receivable and cash guarantees285/8€7k€5k▼

Current assets29/58€5.63M€6.92M▲

Stocks and contracts in progress3€433k€661k▲

Stocks30/36€433k€661k▲

Raw materials and consumables30/31€433k€661k▲

Amounts receivable within one year40/41€2.91M€1.98M▼

Trade receivables40€2.88M€1.66M▼

Other amounts receivable41€31k€325k▲

Cash at bank and in hand54/58€2.02M€4.02M▲

Deferred charges and accrued income490/1€267k€258k▼

Equity and liabilities

Total equity and liabilities10/49€9.32M€10.22M▲

Equity10/15€4.58M€4.58M=

Contributions10/11€2.51M€2.51M=

Capital10€2.51M€2.51M=

Issued capital100€2.51M€2.51M=

Reserves13€1.76M€1.76M=

Non-distributable reserves130/1€251k€251k=

Legal reserve130€251k€251k=

Distributable reserves133€1.51M€1.51M=

Profit (loss) carried forward14€313k€313k=

Amounts payable17/49€4.75M€5.64M▲

Amounts payable after more than one year17€1.00M€1.00M=

Financial debts170/4€1.00M€1.00M=

Subordinated loans170€1.00M€1.00M=

Credit institutions173€0-

Amounts payable within one year42/48€3.72M€4.60M▲

Current portion of amounts payable after more than one year42€0-

Trade debts44€1.26M€1.22M▼

Suppliers440/4€1.26M€1.22M▼

Advances received on contracts in progress46€212k€0▼

Taxes, remuneration and social security45€1.67M€1.56M▼

Taxes450/3€489k€425k▼

Remuneration and social security454/9€1.18M€1.14M▼

Other amounts payable47/48€575k€1.82M▲

Accrued charges and deferred income492/3€28k€44k▲

Income statement Code20232024

Operating income70/76A€23.31M€24.20M▲

Turnover70€21.84M€23.60M▲

Other operating income74€1.47M€596k▼

Operating charges60/66A€22.41M€21.96M▼

Goods for resale, raw materials and consumables60€4.77M€3.41M▼

Purchases600/8€4.81M€3.63M▼

Change in stocks: decrease (increase)609€-41k€-227k▼

Services and other goods61€7.88M€9.11M▲

Remuneration, social security and pensions62€8.37M€7.82M▼

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.36M€1.36M▲

Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€23k€52k▲

Other operating charges640/8€6k€6k▲

Non-recurring operating charges66A-€199k

Operating profit (loss)9901€898k€2.24M▲

Financial income75/76B€36k€340k▲

Recurring financial income75€36k€340k▲

Income from current assets751€36k€98k▲

Other financial income752/9€0€242k▲

Financial charges65/66B€93k€85k▼

Recurring financial charges65€93k€85k▼

Debt charges650€38k€61k▲

Other financial charges652/9€56k€23k▼

Profit (loss) for the period before taxes9903€841k€2.49M▲

Income taxes67/77€284k€690k▲

Taxes670/3€284k€690k▲

Profit (loss) for the period9904€557k€1.80M▲

Profit (loss) for the period to be appropriated9905€557k€1.80M▲

Appropriation of the result

Profit (loss) to be appropriated9906€869k€2.12M▲

Profit (loss) brought forward from the previous period14P€313k€313k=

Profit to be distributed694/7€557k€1.80M▲

Return on contributions (dividend)694€557k€1.80M▲

Social balance

Average headcount (FTE)908798.588.6▼

The notes to these accounts (71 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 36Financial 2Gazette 24Filings 10

2026

03-02

State Gazette act Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)

Permanent representative: Van Durme Pieter-Jan3 facts ▸

General meeting, 07-06-2025
Auditor reappointment, Deloitte Bedrijfsrevisoren BV
Permanent representative, Van Durme Pieter-Jan

2025

01-07

NBB filing Annual accounts filed

fiscal year 2024 · full schema

2024

31-12

Financial Highest result since 2018net €1.80M ▲224%

Net result €1.80M, the highest in the series.

11-09

State Gazette act Resignation: Claire Berger (director)

2 facts ▸

General meeting, 04-07-2024
Director resignation, Claire Berger (director)

05-06

NBB filing Annual accounts filed

fiscal year 2023 · full schema

2023

16-06

NBB filing Annual accounts filed

fiscal year 2022 · full schema

29-03

State Gazette act Reappointments: Regon BV (director) and Deloitte Bedrijfsrevisoren (statutory auditor)

Permanent representative: Yves Gonissen4 facts ▸

General meeting, 04-06-2022
Director reappointment, Regon BV (director)
Permanent representative, Yves Gonissen
Auditor reappointment, Deloitte Bedrijfsrevisoren

2022

01-07

NBB filing Annual accounts filed

fiscal year 2021 · full schema

16-02

State Gazette act Permanent representative: Pieter-Jan Van Durme

Accounting effect4 facts ▸

General meeting, 28-10-2021
Permanent representative, Pieter-Jan Van Durme
Accounting effect, 01-01-2020
Accounting effect, 31-12-2021

2021

04-08

State Gazette act Registered office · Statutes amendment

Registered-office move · Statutes amendment · Capital4 facts ▸

General meeting, 02-08-2021
Registered-office move, Industriepark 7B, 9052 Zwijnaarde
Statutes amendment
Capital, €2.508.550

16-06

NBB filing Annual accounts filed

fiscal year 2020 · full schema

06-05

State Gazette act Resignation: Timothy Oostdyk (manager)

Appointment: Claire Dubois-Berger (director) · Permanent representative: Yves Gonnissen4 facts ▸

General meeting, 16-11-2020
Director resignation, Timothy Oostdyk (manager)
Director appointment, Claire Dubois-Berger (director)
Permanent representative, Yves Gonnissen

Show earlier events

2020

07-12

State Gazette act Appointment: Deloitte Bedrijfsrevisoren (commissaris revisor)

Permanent representatives: Evelien Weyts and Yves Gonnissen4 facts ▸

General meeting, 30-12-2020
Auditor appointment, Deloitte Bedrijfsrevisoren (commissaris revisor)
Permanent representative, Evelien Weyts
Permanent representative, Yves Gonnissen

29-09

NBB filing Annual accounts filed

fiscal year 2019 · full schema · 60 days late

26-02

State Gazette act Resignations: Marcel Oerlemans, Berthold Hackl and Amatsigroup SAS

Permanent representative: Alain Sainsot5 facts ▸

General meeting, 26-09-2019
Director resignation, Marcel Oerlemans (director)
Director resignation, Berthold Hackl (director)
Director resignation, Amatsigroup SAS (director)
Permanent representative, Alain Sainsot

2019

31-12

Financial Back to profitnet €603k

Net result €603k after one loss-making year.

23-09

NBB filing Annual accounts filed

fiscal year 2018 · full schema · 54 days late

09-04

NBB filing Annual accounts filed

fiscal year 2017 · full schema · 252 days late

2018

13-02

State Gazette act Benaming

Name change · Power of attorney4 facts ▸

General meeting
Name change, Eurofins Amatsigroup
Power of attorney, Herbert Houben
Power of attorney, Iedere bestuurder

2017

08-11

State Gazette act Appointments: REGON (managing director) and CREABIOSUPPORT (managing director)

Permanent representatives: Yves GONNISSEN and Annie VAN BROEKHOVEN5 facts ▸

Board meeting, 30-06-2017
Director appointment, REGON (managing director)
Permanent representative, Yves GONNISSEN
Director appointment, CREABIOSUPPORT (managing director)
Permanent representative, Annie VAN BROEKHOVEN

17-10

State Gazette act Resignations: Jean-Paul Prieels, Claire Dubois Berger and Creabiosupport BVBA

Appointments: Timothy Oostdyk, Berthold Hacki and Marcel Oerlemans9 facts ▸

General meeting, 11-09-2017
Director resignation, Jean-Paul Prieels (director)
Director resignation, Claire Dubois Berger (director)
Director resignation, Creabiosupport BVBA (director)
Director appointment, Timothy Oostdyk (director)
Director appointment, Berthold Hacki (director)
Director appointment, Marcel Oerlemans (director)
Board meeting, 11-09-2017
Director resignation, Creabiosupport BVBA (managing director)

28-07

NBB filing Annual accounts filed

fiscal year 2016 · full schema

26-07

State Gazette act Restructuring

Permanent representatives: SAINSOT Alain, GONNISSEN Yves and VAN BROEKHOVEN Annie Florentine Joseph · Merger · Dissolution18 facts ▸

General meeting, 29-06-2017
Merger, absorption, 01-01-2017
Dissolution, 29-06-2017
Merger, absorption, 01-01-2017
Dissolution, 29-06-2017
Capital increase, €2.071.000
Share issue, gewone aandelen op naam zonder aanduiding van nominale waarde, 132218
Name change, Amatsigroup
Permanent representative, SAINSOT Alain
Permanent representative, GONNISSEN Yves
Permanent representative, VAN BROEKHOVEN Annie Florentine Joseph
Board composition, AMATSIGROUP (director)
+6 further facts in this act

16-05

State Gazette act Restructuring

Merger · Share transfer · Accounting effect5 facts ▸

Merger, met fusie door overneming gelijkgestelde verrichting
Share transfer, Amatsigroup S.A. → SEPS Pharma
Accounting effect, 01-01-2017
Merger condition, zonder uitreiking van nieuwe aandelen in het kapitaal van de overnemende vennootschap
Tax provision, artikelen 211 en volgende van het Wetboek van Inkomstenbelastingen 1992; artikelen 11 en 18, §3 van het Wetboek van de belasting over de toegevoegde waarde

16-05

State Gazette act Restructuring

Merger · Accounting effect · Power of attorney3 facts ▸

Merger, absorption, 1 aandeel SEPS Pharma voor 16,6357407 aandelen Q-Biologicals
Accounting effect, 01-01-2017
Power of attorney, Laga

15-05

State Gazette act Appointment: KPMG Bedrijfsrevisoren BV CVBA (statutory auditor)

Permanent representative: Van Linden Kristof3 facts ▸

General meeting, 01-04-2016
Auditor appointment, KPMG Bedrijfsrevisoren BV CVBA (statutory auditor)
Permanent representative, Van Linden Kristof

2016

11-08

NBB filing Annual accounts filed

fiscal year 2015 · full schema · 11 days late

29-04

State Gazette act Appointment: REGON (managing director)

Permanent representative: Yves GONNISSEN · Mandate compensation3 facts ▸

Director appointment, REGON (managing director)
Permanent representative, Yves GONNISSEN
Mandate compensation, REGON

2015

25-02

State Gazette act Resignations: André REMANS, Johan DE TURCK and 9 others

Appointments: REGON, Alain SAINSOT and 4 others · Permanent representatives: Alain SAINSOT and Yves GONNISSEN · Capital34 facts ▸

General meeting, 15-01-2015
Director resignation, André REMANS (director)
Director resignation, Johan DE TURCK (director)
Director resignation, Roger LEYSSENS (director)
Director resignation, Ann-Pascale BIJNENS (director)
Director resignation, LRM Beheer (director)
Director resignation, LRM (director)
Director resignation, REGON (director)
Director appointment, REGON (director)
Director appointment, Alain SAINSOT (director)
Director appointment, Jean-Pierre ARNAUD (director)
Director appointment, Thibaud GACHET (director)
+22 further facts in this act

20-01

State Gazette act Appointment: BDO Bedrijfsrevisoren (statutory auditor)

Permanent representative: Gert MARIS · Share issue · Capital increase12 facts ▸

General meeting, 23-12-2009
General meeting, 07-09-2011
Share issue, Warrantenplan I, warrants
Share issue, Warrantenplan II, warrants
Capital increase
Capital, €437.550
Bank account, KBC Bank, BE49 7490 1036 8271
Statutes amendment
Share cancellation, warrants, PMV
Share cancellation, warrants, SOP
Auditor appointment, BDO Bedrijfsrevisoren (statutory auditor)
Permanent representative, Gert MARIS

2014

17-07

State Gazette act Appointment: Regon BVBА (director)

Registered-office move · Power of attorney4 facts ▸

Board meeting, 27-01-2010
Registered-office move, Agoralaan A bis - 3590 Diepenbeek
Director appointment, Regon BVBА
Power of attorney, Yves Gonnissen

13-06

State Gazette act Resignation: SEPS Pharma (director)

Appointments: André Remans, BVBA Regon and 5 others · Permanent representatives: Yves Gonnissen, Nico Vandervelpen and Debora Dumont · Mandate compensation17 facts ▸

General meeting, 25-04-2014
Director resignation, SEPS Pharma
Director appointment, André Remans (director)
Director appointment, BVBA Regon (director)
Permanent representative, Yves Gonnissen
Director appointment, Johan De Turck (director)
Director appointment, Roger Leyssens (director)
Director appointment, Ann-Pascale Bijnens (director)
Director appointment, NV LRM Beheer (director)
Permanent representative, Nico Vandervelpen
Director appointment, NV LRM (director)
Permanent representative, Debora Dumont
+5 further facts in this act

2013

28-10

State Gazette act Reappointment: BDO Bedrijfsrevisoren Burg. Ven. CVBA (statutory auditor)

Permanent representative: Gert Maris · Mandate compensation4 facts ▸

General meeting, 15-05-2013
Auditor reappointment, BDO Bedrijfsrevisoren Burg. Ven. CVBA (statutory auditor)
Permanent representative, Gert Maris
Mandate compensation, BDO Bedrijfsrevisoren Burg. Ven. CVBA

2011

22-09

State Gazette act Miscellaneous

Share issue · Capital increase · Power of attorney11 facts ▸

General meeting
Share issue, PMV Warrants, 3
Capital increase
Share issue, SOP Warrants, 12000
Capital increase
Power of attorney, Yves Gonnissen
Power of attorney, SEPS PHARMA
Waiver of preemptive rights, wet en statuten, artikel 501 W.V., alle aandeelhouders en warranthouders
Waiver of preemptive rights, wet en statuten, artikel 501 W.V., alle aandeelhouders en warranthouders
Warrant subscription, 3, PMV Warrants
Power of attorney, Yves Gonnissen

2010

11-06

State Gazette act Appointment: BDO Bedrijfsrevisoren Burg CV (statutory auditor)

Permanent representative: Gert Maris3 facts ▸

General meeting, 19-01-2010
Auditor appointment, BDO Bedrijfsrevisoren Burg CV (statutory auditor)
Permanent representative, Gert Maris

18-01

State Gazette act Capital & shares

Share issue · Capital increase · Power of attorney10 facts ▸

General meeting, 23-12-2009
Share issue, A-warrants, 10375
Share issue, B-warrants, 500
Share issue, D-warrants, 3500
Capital increase, €63.250
Power of attorney, Raad van bestuur
Pre emptive rights lifting, opheffing van het voorkeurrecht van de bestaande aandeelhouders bij de uitgifte van de warrants, op basis van verslag raad van bestuur (art. 596 W.V.) en bijzon…
Warrant condition, niet overdraagbaar
Warrant condition, uitoefeningsperiode: vanaf definitieve verwerving tot uiterlijk 5 jaar na definitieve verwerving, waarna automatisch en van rechtswege vervallen
Warrant condition, op naam, om niet, ingeschreven in een warrantregister gehouden op de zetel van de vennootschap

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

6 directors, no change since 2024

Claire Dubois-Berger

Director · since 16-11-2020

Current

REGON

Director · since 15-01-2015 · Private limited company · perm. rep.: Yves GONNISSEN

Current

CREABIOSUPPORT

Managing director · since 30-06-2017 · Private limited company (pre-2019) · perm. rep.: Annie VAN BROEKHOVEN

Not recently confirmed

Berthold Hacki

Director · since 11-09-2017

Not recently confirmed

AMATSIGROUP

Director · since 30-01-2015 · Legal entity · perm. rep.: Alain SAINSOT

Not recently confirmed

Regon BVBА

Director · since 10-07-2014 · Legal entity

Not recently confirmed

04-07-2024 Claire Berger: Resigned as Director

05-06-2021 REGON: Mandate renewed as Director

16-11-2020 Claire Dubois-Berger: Appointed as Director

16-11-2020 Timothy Oostdyk: Resigned as Manager

26-09-2019 Amatsigroup SAS: Resigned as Director

Full history in the Timeline (44 changes) →

Location & real-estate footprint

Registered office, Gent · 2 establishment units since 2010

establishment All 2 establishment units on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Industriepark-Zwijnaarde 7B9052 Gent

Ground area

2.3 ha

Building footprint

2,821 m²

Volume, LiDAR

31,048 m³

3 parcels, Flanders · tallest building 16.4 m, ±5 floors. Linked by address, not a title deed.

2 establishment units

Amatsigroup

Technologiepark-Zwijnaarde 94, 9052 GentManufacture of food products

since 20102.193.541.964

Amatsigroup

Industriepark-Zwijnaarde 7, 9052 GentManufacture of food products

since 20182.285.524.688

3 parcels

Flanders 3 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
44082B0081/00F000	Flanders	1.2 ha	1 · 1,291 m²	15.3 m · 5 fl.
44082B0356/00S000	Flanders	1.0 ha	1 · 768 m²	16.4 m · 4 fl.
44082B0356/00P000	Flanders	762 m²	1 · 762 m²	9.3 m · 1 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1 · via establishment units: 2

3 of 3 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor

DELOITTE Bedrijfsrevisoren BVCurrent

Auditor · represented by Van Durme Pieter-Jan

07-06-2025 → present

Show 5 earlier auditors

BDO Bedrijfsrevisoren Statutory auditor · represented by Gert MARIS succeeded by BDO Bedrijfsrevisoren Burg. Ven. CVBA in 2013	23-12-2009 → 15-05-2013
BDO Bedrijfsrevisoren Burg CV Statutory auditor · represented by Gert Maris succeeded by BDO Bedrijfsrevisoren Burg. Ven. CVBA in 2013	01-01-2009 → 15-05-2013
BDO Bedrijfsrevisoren Burg. Ven. CVBA Statutory auditor · represented by Gert Maris succeeded by KPMG BEDRIJFSREVISOREN BV CVBA in 2015	15-05-2013 → 01-01-2015
Deloitte Bedrijfsrevisoren Auditor succeeded by DELOITTE Bedrijfsrevisoren BV in 2025	30-12-2020 → 07-06-2025
KPMG BEDRIJFSREVISOREN BV CVBA Statutory auditor · represented by Van Linden Kristof succeeded by Deloitte Bedrijfsrevisoren in 2020	01-01-2015 → 30-12-2020

Articles of association

Purpose

1. Het uitvoeren van alle vormen van onderzoek en ontwikkeling op biologische producten, chemische producten, farmaceutische producten, cosmeticaproducten, dieetvoeding en alle…

Full purpose

1. Het uitvoeren van alle vormen van onderzoek en ontwikkeling op biologische producten, chemische producten, farmaceutische producten, cosmeticaproducten, dieetvoeding en alle aanverwante producten, de productie en commercialisatie van de resultaten daarvan. De vennootschap zal alle burgerlijke, industriële, commerciële, financiële, roerende en onroerende handelingen mogen verrichten in rechtstreeks of onrechtstreeks verband met haar doel, die van aard zijn de verwezenlijking ervan te vergemakkelijken of uit te breiden, en die daartoe noodzakelijk, nuttig of zelfs alleen maar bevorderend zijn. 2. Het uitvoeren van onderzoek en ontwikkeling naar nieuwe geneesmiddelen en nieuwe toedieningsvormen, de productie en commercialisatie van de resultaten daarvan. 3. Het verwerven, vervreemden, uitbaten, te gelde maken, commercialiseren en beheren van alle intellectuele eigendommen, eigendoms- en gebruiksrechten, merken, brevetten, tekeningen, licenties enzovoort. 4. Het nemen van participaties onder eender welke vorm in alle bestaande of nog op te richten vennootschappen en ondernemingen. 5. Advies, bijstand, en know-how verlenen in alle domeinen waarin zij competent is, zoals ontwikkeling, onderzoek, design, marketing, promotie, handel in productie, secretariaat, bedrijf- en financieel beheer, en al wat daarmede rechtstreeks of onrechtstreeks verband houdt. 6. Groot- en kleinhandel, aankoop en verkoop van biologische producten, chemische producten, farmaceutische producten, cosmeticaproducten, dieetvoeding en alle aanverwante producten. De vennootschap mag daarenboven belangen nemen, hetzij door deelneming, inbreng of elke andere wijze in alle vennootschappen, ondernemingen, economische samenwerkingsverbanden, die een gelijkluidend, aanvullend of soortgelijk doel nastreven, of die van aard zijn de ontwikkeling van haar onderneming te bevorderen. De vennootschap mag ten voordele van derden tevens alle waarborgen toestaan, alle roerende goederen verpanden, alle onroerende goederen met hypotheek bezwaren. De vennootschap mag optreden als bestuurder, volmachtdrager, mandataris of vereffenaar in andere vennootschappen, zich borg stellen voor derden, bestuurders en aandeelhouders, evenals hun leningen, voorschotten en kredieten toestaan, behoudens de wettelijke beperkingen terzake.

according to the deed of 04-08-2021

Structure & network

Connections & network

31 connected companies

Shared directorsBundled connections

Linked via shared directors

KAASBRIK

Shared director

→

Airobot

Shared corporate director

→

ALRO HOLDINGS

Shared corporate director

→

ARKITE

Shared corporate director

→

Show 27 more companies with a shared director

BELGIAN CYCLING FACTORY

Shared corporate director

→

Blue Foot Membranes

Shared corporate director

→

CAMPUS ENERGYVILLE

Shared corporate director

→

Centrica Business Solutions Belgium

Shared corporate director

→

Complix

Shared corporate director

→

CORDA CAMPUS 2.0

Shared corporate director

→

Cubigo International

Shared corporate director

→

Down2Earth Capital

Shared corporate director

→

DRONEPORT

Shared corporate director

→

FONTAINE HOLDINGS

Shared corporate director

→

Greenville

Shared corporate director

→

INCUBATHOR WETENSCHAPSPARK WATERSCHEI

Shared corporate director

→

Kristalpark III

Shared corporate director

→

Laser Cladding Venture

Shared corporate director

→

LIMBURG REGIONAL AIRPORT

Shared corporate director

→

MACHIELS BUILDING SOLUTIONS

Shared corporate director

→

MATE Ergonomics

Shared corporate director

→

Optiflux

Shared corporate director

→

PRIDIKTIV

Shared corporate director

→

PUNCH POWERTRAIN

Shared corporate director

→

QOMPIUM

Shared corporate director

→

THOR PARK

Shared corporate director

→

TRENDMINER

Shared corporate director

→

UgenTec

Shared corporate director

→

ZONNECENTRALE BERINGEN

Shared corporate director

→

ZONNECENTRALE LIMBURG

Shared corporate director

→

ZONNECENTRALE LOMMEL

Shared corporate director

→

Acquisitions and mergers

2 transactions

Took over:Q-Biologicals

BE 0840.165.203merger by absorption · State Gazette act of 26-07-2017 (2 acts) · effective 01-01-2017

Took over:SEPS Pharma Clinical Trial Manufacturing

BE 0847.498.995merger by absorption · State Gazette act of 26-07-2017 (2 acts) · effective 01-01-2017

Capital and shareholders

Capital over the years

04-08-2021 Capital stated in the act · 2,508,550 EUR · 295,343 shares
26-07-2017 Capital increase of 2,071,000 EUR · to 2,508,550 EUR · 132,218 new shares
25-02-2015 Capital stated in 2 acts · 437,550 EUR · 163,125 shares
18-01-2010 Capital increase of 63,250 EUR

Public money · subsidies and aid

Flemish government

2022 to 2025 · 7 entries · 112,128 EUR awarded · 62,039 EUR paid

Year	Entries	awarded	paid
2025	3	101,048 EUR	50,959 EUR
2024	2	3,157 EUR	3,157 EUR
2023	1	7,753 EUR	7,753 EUR
2022	1	170 EUR	170 EUR

Schemes

O&O-haalbaarheidsstudie

1 entry · 100,000 EUR · 50,000 EUR paid · Fonds voor Innoveren en Ondernemen

Vlaams opleidingsverlof (VOV)

4 entries · 11,161 EUR · 11,161 EUR paid · Departement Werk en Sociale Economie

Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)

2 entries · 967 EUR · 878 EUR paid · Fonds voor Innoveren en Ondernemen

European research

2 projects · 629,445 EUR EU contribution

Programmes

Horizon 2020

2 entries · 629,445 EUR

Projects

New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

Horizon 2020 · participant · 01-01-2017 to 30-09-2021 · 373,125 EUR · NEW DEAL

Boosting advanced doctoral training in innovative colon targeting drugs

Horizon 2020 · participant · 01-01-2021 to 31-12-2024 · 256,320 EUR · COLOTAN

Similar companies · same sector, comparable size

DIAsource ImmunoAssays S.A.

BE 0457.934.723

Ottignies-Louvain-la-Neuve · Eq €4.41M

LABORATOIRE STE-ANNE ET ST-JEAN

Anderlecht · Eq €4.12M

Klinisch Laboratorium Maenhout

BE 0420.196.971

Waregem · Eq €4.04M

Of 698 companies in sector 86910 we hold annual accounts for 520. 263 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification

Legal formPublic limited company

Founded19-10-2007

Fiscal year end31-12

Activities, NACEBEL 2025

72109Other research and development on natural sciences

86910Medical imaging and medical laboratories

21201Manufacture of basic pharmaceutical products and pharmaceutical preparations

46180Agents specialised in the wholesale of other particular products

46389Wholesale of other food products

46450Wholesale of perfume and cosmetics

46460Wholesale of pharmaceutical and medical goods

Sources

Crossroads Bank for EnterprisesNational Bank · 17 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.

Contact details

2 entries

Phone:09/261901

Establishment Gent 2.193.541.964

Fax:09/261920

Establishment Gent 2.193.541.964